BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 8315435)

  • 1. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
    Minasian LM; Motzer RJ; Gluck L; Mazumdar M; Vlamis V; Krown SE
    J Clin Oncol; 1993 Jul; 11(7):1368-75. PubMed ID: 8315435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
    Padrik P; Leppik K; Arak A
    Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.
    Ilson DH; Motzer RJ; Kradin RL; Vogelzang NJ; Bajorin DF; Scher HI; Nanus D; O'Moore P; Marathias K; Bosl GJ
    J Clin Oncol; 1992 Jul; 10(7):1124-30. PubMed ID: 1607918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
    Motzer RJ; Murphy BA; Bacik J; Schwartz LH; Nanus DM; Mariani T; Loehrer P; Wilding G; Fairclough DL; Cella D; Mazumdar M
    J Clin Oncol; 2000 Aug; 18(16):2972-80. PubMed ID: 10944130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
    J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
    Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
    Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study.
    Fosså SD; Martinelli G; Otto U; Schneider G; Wander H; Oberling F; Bauer HW; Achtnicht U; Holdener EE
    Ann Oncol; 1992 Apr; 3(4):301-5. PubMed ID: 1390305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    Atzpodien J; Kirchner H; Jonas U; Bergmann L; Schott H; Heynemann H; Fornara P; Loening SA; Roigas J; Müller SC; Bodenstein H; Pomer S; Metzner B; Rebmann U; Oberneder R; Siebels M; Wandert T; Puchberger T; Reitz M;
    J Clin Oncol; 2004 Apr; 22(7):1188-94. PubMed ID: 14981107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.
    Vogelzang NJ; Lipton A; Figlin RA
    J Clin Oncol; 1993 Sep; 11(9):1809-16. PubMed ID: 8355047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
    Aass N; De Mulder PH; Mickisch GH; Mulders P; van Oosterom AT; van Poppel H; Fossa SD; de Prijck L; Sylvester RJ
    J Clin Oncol; 2005 Jun; 23(18):4172-8. PubMed ID: 15961764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
    J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
    Negrier S; Escudier B; Lasset C; Douillard JY; Savary J; Chevreau C; Ravaud A; Mercatello A; Peny J; Mousseau M; Philip T; Tursz T
    N Engl J Med; 1998 Apr; 338(18):1272-8. PubMed ID: 9562581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Berdah JF; Benhammouda A; Salze P; Monnier A; Paule B; Guillet P; Chretien Y; Brewer Y; Di Palma M; Untereiner M; Malaurie E; Tadrist Z; Pavlovitch JM; Hauteville D; Mejean A; Azagury M; Mayeur D; Lucas V; Krakowski I; Larregain-Fournier D; Abourachid H; Andrieu JM; Chastang C
    J Clin Oncol; 1998 Jul; 16(7):2505-13. PubMed ID: 9667271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
    Marincola FM; White DE; Wise AP; Rosenberg SA
    J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study.
    Artaç M; Çoşkun HŞ; Korkmaz L; Koçer M; Turhal NS; Engin H; Dede İ; Paydaş S; Öksüzoğlu B; Bozcuk H; Demirkazık A
    Clin Genitourin Cancer; 2016 Aug; 14(4):e347-53. PubMed ID: 27236771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
    Négrier S; Caty A; Lesimple T; Douillard JY; Escudier B; Rossi JF; Viens P; Gomez F
    J Clin Oncol; 2000 Dec; 18(24):4009-15. PubMed ID: 11118461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
    Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
    J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.
    Pyrhönen S; Salminen E; Ruutu M; Lehtonen T; Nurmi M; Tammela T; Juusela H; Rintala E; Hietanen P; Kellokumpu-Lehtinen PL
    J Clin Oncol; 1999 Sep; 17(9):2859-67. PubMed ID: 10561363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
    Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
    Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.